Damora Therapeutics (DMRA) Preferred Stock Liabilities (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Preferred Stock Liabilities came in at $1.3 million in Q1 2026, down 1.4% YoY from $1.4 million in Q1 2025, and little changed on a QoQ basis from $1.3 million in Q4 2025.
Damora Therapeutics (DMRA) Preferred Stock Liabilities (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 5 years of Preferred Stock Liabilities data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Preferred Stock Liabilities fell 1.4% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 1.4% YoY) and the FY2025 annual result came in at $1.3 million, down 1.4% from the prior year.
- Preferred Stock Liabilities steadied at $1.3 million in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $1.4 million in Q4 2024 to a low of $1.3 million in Q2 2025.
- A 3-year average of $1.3 million and a median of $1.3 million in 2025 frame the typical range for Preferred Stock Liabilities.
- The widest YoY moves for Preferred Stock Liabilities: up 1.4% in 2025, down 1.4% in 2025.
- Tracing DMRA's Preferred Stock Liabilities over 3 years: stood at $1.4 million in 2024, then fell by 1.4% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
- The last three Preferred Stock Liabilities figures came in at $1.3 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.34 Mn |
| Dec 31, 2025 | 1.34 Mn |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Sep 30, 2020 | 181.02 Mn |
| Jun 30, 2020 | 106.21 Mn |
| Dec 31, 2019 | 119.62 Mn |
| Sep 30, 2019 | 13.41 Mn |